mRNA Technology, Ansaldi (Alisa): "Flexibility and effectiveness are the advantages"

"Products available within 30-40 days improve public health management"

"The mRNA vaccine can offer great advantages. First of all, flexibility both in terms of production timing and quantity, something that constantly characterizes both central management and the management of colleagues in the territory of the active vaccine", avoiding "excesses or shortages in warehouses. Having the possibility of a vaccine that, within 30 or 40 days, can be available again, thanks to mRNA technology, represents a great advantage both in terms of quantity and timeliness". This is particularly important in "a public system, which can so quickly respond even in emergency terms". Thus Filippo Ansaldi, general director of the Ligurian Health Authority (Alisa), in his speech today in Genoa at the meeting on the theme 'The innovation of mRNA technology: from scientific potential to opportunities for regional healthcare', which was held at the Palazzo della Regione Liguria.

"Another great advantage for public health" is linked to the fact that mRNA vaccines are "able to provide an increased response, particularly effective - explains Ansaldi - as they have demonstrated" against Covid, but also against respiratory syncytial virus (RSV), "particularly in the older population. This is a great advantage, both to target public health resources more effectively and efficiently and obtain the maximum results - if our resources are obviously not infinite - and, on the other hand, to obtain the maximum advantage from the point of view of communication, but also objectively of the burden", of the impact of the pathology "in the" healthcare network.